Hemu Gene
Hemu Gene is a gene therapy technology developer. It has two gene editing platforms: lentivirus, CRISPR and Cas.
Hemu Gene is active in the biopharma, biotechnology, health care, medical space based in Asia-Pacific (APAC), founded in 2021.
Within the biopharma, biotechnology, health care, medical space, the company focuses on its core offering rather than a broad product line.
The company is recorded as being based in Asia-Pacific (APAC).
It is recorded at the Series_A stage.
Recorded headcount: c_00051_00100 employees.
It has disclosed roughly $30M in funding.
| Sector | Biopharma, Biotechnology, Health Care, Medical |
|---|---|
| Headquarters | Asia-Pacific (APAC) |
| Founded | 2021 |
| Employees | c_00051_00100 |
| Stage | series_a |
| Total funding | $30,000,000 |
Website: hemogen.cn
Browse related
Sign in to view the contact information we hold for Hemu Gene.
Create a free account
Create a free account